AbbVie Inc. Days of Inventory on Hand

Days of Inventory on Hand of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Days of Inventory on Hand growth rates and interactive chart.

Highlights and Quick Summary

  • Annual Days of Inventory on Hand for 2020 was 85.58 (a -1.64% decrease from previous year)
  • Annual Days of Inventory on Hand for 2019 was 87.0 (a 12.23% increase from previous year)
  • Annual Days of Inventory on Hand for 2018 was 77.52 (a -9.94% decrease from previous year)
  • Twelve month Days of Inventory on Hand ending September 29, 2021 was 64.93 (a -4.8% decrease compared to previous quarter)
  • Twelve month trailing Days of Inventory on Hand decreased by -18.76% year-over-year
Trailing Days of Inventory on Hand for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
64.93 68.21 68.82 79.93
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Days of Inventory on Hand of AbbVie Inc.

Most recent Days of Inventory on Handof ABBV including historical data for past 10 years.

Interactive Chart of Days of Inventory on Hand of AbbVie Inc.

AbbVie Inc. Days of Inventory on Hand for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 85.58
2019 87.0
2018 77.52
2017 86.07
2016 90.65
2015 139.43
2014 92.69
2013 91.63
2012 88.34
2011 68.61
2010 71.1

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.